Why might an IGeneX panel be ordered for brain fog?
One report may use several methods, test several germs, and show both company and standard rules. It is not one yes-or-no Lyme answer. One band, an old antibody, an early negative sample, or a test without FDA clearance can take over the whole workup. Before repeating panels or starting treatment, check whether each result fits the exposure, symptoms, dates, and standard testing path.
Possible exposure
Testing starts with a plausible infection
A tick location, expanding rash, fever, facial weakness, heart symptoms, joint swelling, or another compatible sign gives the test a clinical question. Brain fog alone does not select a panel.
The mixed-method problem
One order can contain several kinds of evidence
Antibody screens, immunoblots, PCR, T-cell tests, and tests for other infections answer different questions. They cannot share one accuracy claim.
What the clinician needs
The report needs its method and timing
Keep each result with its sample, draw date, lab rules, FDA status, first symptom day, exposure, past infection, and treatment history.
A positive result may show antibodies or a method-specific signal. A negative result may be too early, use the wrong specimen, or answer only part of the question. Neither result proves what is causing brain fog on its own.
Save this test
Save the panel as separate linked results
Use My Fog to keep each assay beside its method, specimen, criteria, timing, and clinical question. That stops one band or one brand-level label from taking over the full workup.
Keep the original report. My Fog stores the test details, exposure dates, symptoms, and next questions you enter.
How age, pregnancy, immune health, exposure, and timing affect the panel
IGeneX panels do not have one normal range for age or sex. Age, pregnancy, immune health, symptom dates, exposure, and the exact test change the health question. Each test still uses its own printed rules.
Babies and young children
Use a pediatric clinician and the child's actual exposure, rash, fever, neurologic findings, heart symptoms, joint swelling, and growth. Do not apply an adult specialty-panel shopping list or start treatment from a report without pediatric review.
Children and teenagers
Testing starts with exposure and matching signs. A typical expanding rash in the right setting can be diagnosed from the clinical picture. Facial weakness, severe headache, fainting, chest pain, a racing heart, or a swollen joint needs prompt medical review.
Adult women and men
Use the same proven test rules for women and men. A 2026 study of 243 adults with early Lyme disease found differences by sex and menopause in two-step antibody results. It did not set different cutoffs or prove specialty panels are accurate.
Pregnancy and breastfeeding
Pregnancy changes the urgency of assessment and the safety of treatment choices, not the meaning of an unverified band. Contact the obstetric and treating teams promptly after a compatible rash, fever, new neurologic symptoms, or a concerning exposure, and do not self-start antibiotics or herbs.
Older adults
Heart, neurologic, balance, medication, and competing medical causes deserve extra attention. Do not let a broad panel delay assessment of fainting, new weakness, confusion, chest symptoms, or another acute illness.
Weaker immunity or early antibiotics
A weak immune system and treatment before the draw can make antibody results harder to read. Record the medicine, dose time, and draw date. Ask a clinician to choose the right sample and check other diagnoses instead of repeating the same panel automatically.
Before an IGeneX panel
Get the exact panel code and test list before the draw. Lyme ImmunoBlot Panel 1, Lyme/TBRF panels, broad tick-borne panels, and co-infection panels contain different tests and may need different tubes.
Ask what question each part of the panel is meant to answer. Find out what would change after a positive, negative, or unclear result.
IGeneX says ordinary blood collection does not require fasting. Eat and drink normally unless another test on the same order has its own instructions. Do not stop prescriptions or start an antibiotic challenge unless the prescribing clinician gives a separate, safe reason.
Use the current collection instructions for the exact order. The domestic blood kit can include serum separator, EDTA, and heparin tubes. Labels need the patient's identifying details and collection date, and tube handling differs by specimen.
Some samples are time-sensitive. Current IGeneX directions say to draw and ship IGXSpot and culture-enhanced PCR samples on Monday, Tuesday, or Wednesday. They must reach the lab within 48 hours, stay at room temperature, and not be chilled or frozen. Follow the kit if its directions change.
Before paying, confirm the current price, insurance or Medicare paperwork, draw fee, shipping, refund rules, and whether a standard local test should come first. The lab's current directory lists many panels, not one universal IGeneX panel.
Write down where and when the tick bite happened, how long the tick was attached, and when a rash appeared. Bring rash photos. Add fever, facial weakness, severe headache, a racing heart, fainting, joint swelling, numbness, past Lyme disease, vaccines, antibiotics, immune suppression, pregnancy, and symptom dates.
Name the exact order
Save the panel code, laboratory requisition, every component test, specimen type, and collection date. A collection kit is not the test, and a brand name is not a result.
Check the pathway
Mark the test method. It may use the standard or modified two-step antibody path, an FDA-cleared iDart test, the lab's own rules, PCR, or another method.
Read each result separately
Keep the overall call, individual bands, IgM or IgG class, organism, specimen, cutoff, and printed interpretation together. Do not combine unlike methods into one score.
Record the illness and exposure dates with the report
Add days since symptom onset, rash timing, treatment before collection, prior infection, and exposure location. These can change what a positive or negative line means.
Decide what needs to be checked next
Ask whether the result supports the suspected diagnosis, needs standard confirmation, needs a later sample, or should send the workup toward another cause.
How to read an IGeneX result
Start with the exact test and lab call. Then add the method, sample, lab rules, FDA status, draw date, symptom length, exposure, past infection, treatment, and the rest of the testing path.
Every included assay is negative or not detected
All included assays reported negative or not detected under their named criteria
This lowers support only for the organisms and methods actually tested in that collection window. It does not rule out very early antibody-negative Lyme disease, an untested organism, a weak specimen for direct detection, or another cause of symptoms.
Equivocal, isolated, or discordant result
Equivocal, indeterminate, isolated band, isolated IgM, mixed criteria, or discordant component results
Do not average the lines into one positive panel. Check the full two-step path, symptom timing, exact lab rules, past infection, and false reactions. Ask whether a later standard sample or another diagnosis would answer the question.
Positive antibody result under the named criteria
Positive antibody pathway under the exact printed FDA-cleared or laboratory criteria
This may support current or prior exposure when the clinical history and intended use fit. It doesn't by itself date the infection, prove that Lyme disease is causing ongoing brain fog, or show that live bacteria remain after treatment.
PCR, culture-enhanced PCR, or T-cell result
DNA detected, culture-enhanced result, T-cell result, or another non-serology component
Read the germ, method, sample, quality controls, proof behind the test, and its false-positive and false-negative limits. A PCR, culture, or T-cell result does not get the accuracy or FDA status of an antibody test elsewhere in the panel.
Clearance for one assay does not validate every test in the panel
Both iDart immunoblots have named FDA clearances and intended uses. Other panel components and internal criteria need their own evidence and regulatory check.
See research details
The research details separate current FDA records and CDC guidance from older studies, the lab's own rules, and new research linked to the manufacturer.
Save the exact code and component list from the order date. Prices and bundles can change, so do not use an old webpage or somebody else's report to interpret yours.
Look for the exact assay name and 510(k) number. Do not describe a collection kit, laboratory brand, internal interpretation rule, PCR, T-cell assay, or multi-test panel as FDA-cleared unless its own record says so.
Read the result beside exposure probability, symptoms, symptom duration, rash, prior Lyme disease, treatment, and the rest of the diagnostic pathway.
The studies gave these agreement estimates with confidence intervals. They don't promise the test is 90 to 98 percent accurate for every person, disease stage, or clinic population.
Ask the clinician to name the algorithm on your report. A second-tier result without a known first tier, or a mix of company and CDC calls, needs cautious interpretation.
Put symptom onset, rash date, prior infection, and antibiotics next to the collection date. Do not use repeat antibody testing to monitor cure.
Use this as a warning about criteria and version, not as a final judgment on every present-day IGeneX test. Save whether the report used CDC, FDA-cleared kit, or internal criteria.
Do not count individual bands at home or transfer one laboratory's rule to another assay. Use the complete validated interpretation printed for the exact test.
Use the FDA decision summaries for intended use and cleared performance. Treat the 2026 paper as new manufacturer-affiliated evidence that still needs independent clinical replication.
Do not invent male, female, or menopause-specific panel criteria. A clinician can use the finding as context when a well-timed serology result disagrees with symptoms, examination, and other results.
What to do while the result is checked
Food cannot change an antibody band or PCR result. Keep a clear exposure record, prevent another tick bite, skip unproven treatment, and bring one clear question to the next visit.
Build the tick and symptom timeline
Record where and when the bite happened and how long the tick was attached. Add rash changes, fever, facial weakness, headache, a racing heart, fainting, joint swelling, numbness, treatment dates, and brain-fog changes. A dated rash photo beside a ruler preserves its size.
Prevent the next tick bite
Use EPA-registered repellent as directed, check clothing and skin after outdoor exposure, shower soon after coming indoors, and remove attached ticks promptly with fine-tipped tweezers. Save the date and location. A commercial tick test isn't a reliable way to diagnose you.
Ask the value question before paying
For each part, ask what a positive, negative, or unclear result would change. Check whether the test is FDA-cleared for that use. Ask whether a standard local test should come first or fewer tests could reach the same decision.
Keep ordinary supports ordinary
Eat regular tolerated meals, drink enough fluid, protect sleep, pace activity during an acute illness, and keep existing medicines stable unless the prescriber changes them. These steps support recovery but do not treat Lyme disease or turn a test positive or negative.
Do not treat the report yourself
Avoid antibiotic challenges, leftover antibiotics, prolonged antibiotics, herbal antimicrobial stacks, binders, detox plans, and severe food restriction based on bands or color flags. Bring the exact report to a clinician who can compare it with the recommended pathway and other causes.
Get urgent care for fainting, chest pain, major trouble breathing, a very slow or uneven heartbeat, new facial or limb weakness, confusion, or fast-worsening illness. A severe headache with a stiff neck or a badly swollen joint with fever also needs urgent care. Do not wait for a specialty panel.
What to save before the next appointment
Keep these together
- Panel name, panel code, order date, price paid, insurance or Medicare paperwork, laboratory, report version, and ordering clinician
- Every component assay, method, organism, specimen, collection date, result, units, bands, cutoff, interpretation criteria, FDA status, and 510(k) number if listed
- Tick location and date, attached-tick details, rash photos and dates, fever, facial weakness, heart symptoms, joint swelling, neurologic symptoms, and when brain fog changed
- Prior Lyme disease, Lyme vaccination history, antibiotics and dates, immune suppression, pregnancy, other diagnoses considered, standard tests already done, and clinician interpretation
- The decision for each line. Record whether to treat it as support, confirm it, repeat it at a set time, use another method, treat a diagnosed illness, or keep looking
Question for the visit
“Which exact assay and criteria should guide this result, does it fit the exposure and timing, does any line need standard confirmation or a later sample, and which other causes still need evaluation?”
Sources for IGeneX Lyme and Tick-Borne Panels
Current panel inventory, panel codes, methods, specimens, and commercial ordering context
Current component list, test numbers, specimen requirement, and manufacturer description
Tube handling, labeling, draw days, shipping, temperature, and time-sensitive specimen rules
Two-step testing, early false negatives, antibody persistence, cross-reactions, and the 30-day IgM limit
Standard and modified two-tier interpretation, low-probability testing, criteria, discordant results, and report wording
Cleared intended use, limitations, clinical cohorts, positive and negative percent agreement, and healthy-control findings
Cleared intended use, limitations, 997-sample performance, CDC panel results, healthy controls, and cross-reactivity
Current federal LDT rule status after the 2025 court decision and regulatory reversion
Difference between laboratory quality oversight, analytical validation, FDA review, and clinical validity
Four-laboratory Lyme serology comparison, interlaboratory discordance, in-house criteria, and study-era limits
Alternative single-tier immunoblot criteria, healthy-control false-positive rates, and disclosed test-development interests
Sex and menopause differences in early Lyme presentation and two-tier seropositivity among 243 US adults
AAN, ACR, and IDSA Lyme guideline PubMed record
New recombinant-antigen iDart immunoblot research and manufacturer-affiliated evidence context
See each claim's sources
procedure
IGeneX is a laboratory offering many panels and individual assays, so the exact panel code and included tests are required before a result can be interpreted.procedure
Ordinary IGeneX blood collection does not require fasting, while some IGXSpot and culture-enhanced PCR specimens have special weekday, shipping, temperature, and 48-hour handling requirements.limitation
FDA clearance applies to the two named iDart ImmunoBlot kits and their intended uses, not automatically to the IGeneX brand or every component of a commercial panel.limitation
CLIA certification addresses laboratory quality and analytical performance requirements but does not by itself establish FDA clearance or the clinical validity of every laboratory-developed test.interpretation
CDC recommends two-step Lyme serology with FDA-cleared assays and requires both steps for the final interpretation when standard or modified two-tier testing is used.interpretation
Lyme serology can be falsely negative during the first 4 to 6 weeks, antibodies can persist for months to years, and IgM should be disregarded after more than 30 days of illness.accuracy
FDA decision summaries report study-specific positive and negative percent agreement for both iDart immunoblots, which should not be presented as universal accuracy for every disease stage or population.accuracy
A 2014 four-laboratory comparison found substantial interlaboratory discordance and reduced specificity at one specialty laboratory when in-house criteria were used, but it predates the current cleared iDart assays.accuracy
A 2023 study found higher false-positive or equivocal rates in healthy controls with two alternative single-tier immunoblot criteria than with CDC two-tier criteria, but it did not validate the final cleared iDart assays.accuracy
The July 2026 recombinant-antigen immunoblot paper is new peer-reviewed evidence from researchers affiliated with IGeneX and ID-FISH Technology and should not be described as independent replication.population
A 2026 cohort of 243 adults with early Lyme disease found sex and menopause differences in two-tier seropositivity, but did not establish separate cutoffs or validate IGeneX panels.